Anti-Epstein-Barr Virus IgG Avidity ELISA kit (VCA) (ab222940)
Key features and details
- Sample type: Cit plasma, Hep Plasma, Serum
- Detection method: Colorimetric
- Assay type: Indirect
- Reacts with: Human
Overview
-
Product name
Anti-Epstein-Barr Virus IgG Avidity ELISA kit (VCA)
See all IgG kits -
Detection method
Colorimetric -
Sample type
Serum, Hep Plasma, Cit plasma -
Assay type
Indirect -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
The Anti-Epstein-Barr Virus IgG ELISA (Enzyme-Linked Immunosorbent Assay) kit (VCA) (ab222940) is designed for the qualitative determination of Epstein-Barr virus viral capsid (VCA)-specific IgG avidity in human serum or plasma (citrate, heparin) to differentiate between acute and past infection. This kit can be used with Human Anti-Epstein Barr virus IgG ELISA Kit (EBV-VCA) (ab108730).
Microplates are coated with specific antigens to bind the corresponding antibodies of the sample (dual pipetting). After washing the wells to remove all unbound sample material, one well is incubated with reagent and the corresponding well with washing buffer. The reagent removes the low-avidity antibodies from the antigens whereas the high-avidity ones are still bound to the specific antigens. After a second washing step to remove the rest of reagent and low-avidity antibodies, a horseradish peroxidase (HRP) labeled conjugate is added. This conjugate binds to the captured antibodies. In a third washing step unbound conjugate is removed. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product.
The intensity of this product is proportional to the amount of specific antibodies in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint color.
Absorbance at 450/620 nm is read using an ELISA microwell plate reader.
-
Notes
The presence of IgG antibodies to Epstein-Barr Virus indicates the occurrence of the infection but does not distinguish between recent and past infection. Specific IgM antibodies are first detected approximately in ten days and peak at about four weeks post infection. They may persist for several months after acute infections. Based on the evidence that antibody avidity gradually increases after exposure to an immunogen, avidity of IgG antibodies can be used as a marker for distinguishing recent primary from long-term infections. Avidity describes the binding strength of a specific antibody to its antigen. Low-avidity IgG antibodies indicate a primary infection, whereas the presence of IgG antibodies with high avidity points to persistency or reactivation of infection.
-
Platform
Pre-coated microplate (12 x 8 well strips)
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 1 x 96 tests Bottle 1 unit Epstein-Barr Virus (VCA) IgG Control High 1 x 2ml Epstein-Barr Virus (VCA) IgG Control Low 1 x 2ml Reagent 1 x 15ml -
Research areas
-
Cellular localization
Secreted -
Alternative names
- Ig gamma 1 chain C region
- Ig gamma 2 chain C region
- Ig gamma 3 chain C region
see all -
Database links
- Entrez Gene: 3500 Human
- Entrez Gene: 3501 Human
- Entrez Gene: 3502 Human
- Entrez Gene: 3503 Human
- SwissProt: P01857 Human
- SwissProt: P01859 Human
- SwissProt: P01860 Human
- SwissProt: P01861 Human
see all
Images
-
Specific antigens are coated on the 96-well plate, controls or test samples are added to the well and incubated. The wells are washed to remove any unbound Human anti-antigen antibodies (Ig). A horseradish peroxidase (HRP) labelled anti-Human Ig conjugate is added to the wells. TMB is then catalyzed by the HRP to produce a blue color product that changes to yellow after adding an acidic stop solution. The intensity of yellow coloration is directly proportional to the amount of Human anti-antigen Ig captured on the plate.